A while back I was speaking to a hedge-fund manager about Biotech. “We don’t do biotech,” he said. Why? I asked. “We don’t understand it,” he said.

I didn't understand this, especially since I had recently learned that biotech has been outperforming the S&P for the last 10 years. So I set out to find out what was going on. What ensued was three months of research and collaboration on the biotech market.

Yes, DNA can be scary even for those of you who took advanced genetics courses in the university. Yet it should not be ignored. The companies that are coming up with innovative new drug discoveries and biotech tools are minting money. You need to learn.

Our newly published report, “The Best of Biotech: Life-Sciences Innovation,” is designed to teach you enough to become familiar with the most important trends in biotech -- and make money from it, too.

Biotech is revolutionizing medicine in much the same way the PC revolutionized the information technology market. Your entire genome can now be mapped for less than $10,000 -- down from nearly $1 million just a decade ago. This is the Moore’s law of medicine in action.

It’s a full-blown, technology-driven cycle of innovation that’s driving biotech. New breakthroughs in drugs, diagnostics, and medical devices are making healthcare more high-tech than ever, extending life and bringing cures to formerly mysterious diseases. Investors have long been attracted by the innovation and potentially large returns in the life sciences and biotechnology sector. In the past five years, biotech has emerged as one of the best-performing technology sectors.

Biotech is the most underserved market on Wall Street. There are very few specialist analysts who can understand it and cover it. Not many glossy business magazines assign reporters to cover the beat. That’s why I enlisted my Dad, Rod Raynovich, who is a biotech expert, to help research and write the report. He spent his entire career in the medical diagnostics and biotech industry. He now researches and consults in the biotech market, exclusively.

I had the idea for a biotech report after I found out that Rod Raynovich's biotech portfolio, which he publishes on www.raygent.com, was up more than 100% in 2010. I'm a big fan of the need to actually make calls and pick stocks, so I insisted that this report have a model portfolio, which it does. We combed the biotech universe for the best companies and those with attractive valuations.

The finished product is one of the most definitive biotech investment reports to date. The 100% in a year sounds great (remember, past performance is not guarantee of future results). These are market-beating numbers. And while I believe his methodology contributes to the outperformance, it also helps that biotech is in a roaring bull market. General biotech indices are up more than 40% over the last five years. In 2008, biotech was a port in the financial storm.

You might now think, “Well, if it’s outperformed it’s certainly ready to underperform for the next five years.” That’s a fair concern. But the reason that I am still bullish on biotech -- and standing by this report -- is that many of the factors driving the biotech market are secular, or long-term, in nature.

In this report, we review the top trends in the biotech sector, break down some of the leading market segments, and provide a list of the leading biotech companies. In addition, the report includes a guide to entering the market via exchange-trade funds (ETFs), mutual funds, or a model portfolio of individual biotech stocks that we have selected.

So, if you are interested in adding a biotech component to your portfolio -- whether you want to buy ETFs, funds, or even individual stocks -- it’s all in this report. It will tell you everything you need to get into one of the best-performing market segments.